Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Contact

News

Penthrox approved in Iceland

Jan 22, 2018Mark EdwardsNews

22 January 2018

ASX Announcement

Penthrox approved in Iceland

Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Iceland.

The Icelandic Medicines Agency issued the Marketing Authorisation on 16 January 2018 making Penthrox available for sale effective immediately.

For the full announcement, please refer to the following link – ASX Announcement – Penthrox Approval in Iceland

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY23 ASX Announcement

    31 August 2023 ASX Announ...

  • Medical Developments International Ltd awarded up to $1.5M in funding for next generation Penthrox® device

    Media Announcment Medical...

  • FY23 Half Year ASX Announcement

    24 February 2023 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter